Trial
NCT03810105
A Study of Olaparib and Durvalumab in Prostate Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
—
Condition
Prostate Cancer
Intervention
Olaparib
Why stopped
Due to low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-09